Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: STM007
MIFTS: 50

Stomatitis

Categories: Oral diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Stomatitis

About this section

MalaCards integrated aliases for Stomatitis:

IMPROVED
Name: Stomatitis 11 75 53 43 14 16 71

Classifications:

MalaCards categories:
Anatomical: Oral diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:9637
MeSH 43 D013280
NCIt 49 C26887
SNOMED-CT 68 95361005
ICD10 31 K12.1
UMLS 71 C0038362
Sources

Summaries for Stomatitis

About this section

Disease Ontology: 11 A mouth disease that is characterized by inflammation of the mouth and lips.

MalaCards based summary: Stomatitis is related to viral infectious disease and ebola hemorrhagic fever, and has symptoms including enanthema, oral manifestations and oral pain. An important gene associated with Stomatitis is VDI (Vesicular Stomatitis Virus Defective Interfering Particle Suppression), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Benzocaine and Tannic acid have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, breast and lung, and related phenotype is immune system.

Wikipedia: 75 Stomatitis is inflammation of the mouth and lips. It refers to any inflammatory process affecting the... more...
Sources

Related Diseases for Stomatitis

About this section

Diseases related to Stomatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 657)
# Related Disease Score Top Affiliating Genes
1 viral infectious disease 31.3 TNF RIGI IFNA2 EIF2AK2
2 ebola hemorrhagic fever 31.3 TNF RIGI IFITM3 BST2
3 newcastle disease 31.0 TNF RIGI EIF2AK2
4 mouth disease 30.9 RIGI IFITM3 IFI35 ATG5 ATG12
5 avian influenza 30.6 TNF RIGI IFITM3
6 influenza 30.5 RSAD2 RIGI NUP98 IFITM3 IFITM2 EIF2AK2
7 hepatitis c virus 30.5 RIGI LDLR IFITM3 EIF2AK2 ATG5
8 chikungunya 30.4 TNF RSAD2 RIGI IFITM3
9 common cold 30.4 TNF IFNA2 CSF2
10 hepatitis c 30.4 RIGI IFNA2 IFITM3 EIF2AK2 ATG5
11 hepatitis 30.2 RIGI IFNA2 IFITM3 EIF2AK2 ATG5
12 gastroenteritis 30.1 TNF IFNA2 CSF2
13 hepatitis b 30.1 TNF RIGI IFNA2 EIF2AK2
14 west nile virus 30.0 RSAD2 RIGI IFITM3 IFITM2
15 dengue virus 30.0 RSAD2 RIGI IFITM3 IFITM2
16 acquired immunodeficiency syndrome 29.9 TNF IFNA2 CSF2
17 rift valley fever 29.8 IFITM3 IFITM2 EIF2AK2
18 myelodysplastic syndrome 29.5 TNF NUP98 IFNA2 EIF2AK2 CSF2
19 aphthous stomatitis 11.7
20 marshall syndrome 11.5
21 noma 11.5
22 denture stomatitis 11.5
23 ulcerative stomatitis 11.4
24 periodic fever, immunodeficiency, and thrombocytopenia syndrome 11.1
25 angular cheilitis 11.0
26 hand, foot and mouth disease 11.0
27 necrotizing ulcerative gingivitis 11.0
28 defective interfering particle induction, control of 11.0
29 riboflavin deficiency 11.0
30 methylmalonic aciduria and homocystinuria, cblf type 10.9
31 neutropenia, nonimmune chronic idiopathic, of adults 10.9
32 lymphoproliferative syndrome 3 10.9
33 5-fluorouracil poisoning 10.9
34 pharyngitis 10.8
35 familial mediterranean fever 10.8
36 lymphadenitis 10.7
37 cervical adenitis 10.6
38 behcet syndrome 10.6
39 vaccinia 10.5
40 herpes simplex 10.5
41 mucositis 10.5
42 rabies 10.5
43 gingivitis 10.5
44 lichen planus 10.5
45 candidiasis 10.5
46 vulto-van silfhout-de vries syndrome 10.4
47 glossitis 10.4
48 exanthem 10.4
49 oral candidiasis 10.4
50 human immunodeficiency virus type 1 10.4

Graphical network of the top 20 diseases related to Stomatitis:



Diseases related to Stomatitis
Sources

Symptoms & Phenotypes for Stomatitis

About this section

UMLS symptoms related to Stomatitis:


enanthema; oral manifestations; oral pain; burning mucosal; sore roof of mouth (symptom); oral mucosal blisters

MGI Mouse Phenotypes related to Stomatitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.47 ADAR ATG5 BST2 CSF2 EIF2AK2 IFI35
Sources

Drugs & Therapeutics for Stomatitis

About this section

Drugs for Stomatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 311)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
2
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
3
Adenosine Approved, Investigational Phase 4 58-61-7 60961
4
Ethanol Approved Phase 4 64-17-5 702
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
7
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
8
Hexetidine Approved, Investigational Phase 4 141-94-6 3607
9
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
10
Ofloxacin Approved Phase 4 82419-36-1 4583
11
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
12
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
13
Promethazine Approved, Investigational Phase 4 60-87-7 4927
14
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
15
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
16
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
17
Povidone K30 Approved, Experimental Phase 4 9003-39-8 6917 131751496
18
Simethicone Approved Phase 4 8050-81-5
19
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
20
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4 96919
21
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
22
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
23
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
24
Lipoic acid Approved, Investigational, Nutraceutical Phase 4 1077-27-6, 1200-22-2 864 445125 6112
25
Diethyl ether Experimental Phase 4 60-29-7 3283
26 Narcotics Phase 4
27 Analgesics, Opioid Phase 4
28
Sodium Hypochlorite Phase 4
29 Eusol Phase 4
30 Castor Phase 4
31 Epinephryl borate Phase 4
32 Citrate Phase 4
33 Cytochrome P-450 Enzyme Inhibitors Phase 4
34 Anti-Infective Agents Phase 4
35 Chlorhexidine gluconate Phase 4
36 Anti-Infective Agents, Local Phase 4
37 Disinfectants Phase 4
38 Folate Phase 4
39 Vitamins Phase 4
40 Vitamin B9 Phase 4
41 Vitamin B Complex Phase 4
42 Antioxidants Phase 4
43 Alpha-lipoic Acid Phase 4
44 Immunologic Factors Phase 4
45 Adjuvants, Immunologic Phase 4
46 Viscosupplements Phase 4
47 Anti-Ulcer Agents Phase 4
48 Aluminum hydroxide, magnesium hydroxide, drug combination Phase 4
49 Antacids Phase 4
50 Blood Substitutes Phase 4

Interventional clinical trials:

(show top 50) (show all 296)
# Name Status NCT ID Phase Drugs
1 Efficacy of Two Different Oral Hygiene Regimens on the Incidence and Severity of Oral Mucositis in Patients Receiving Hematopoietic Stem Cell Transplantation - A Randomized Controlled Trial Unknown status NCT02662374 Phase 4 .02% Chlorohexidine Gluconate;3% Sodium Bicarbonate;Nystatin 10000U/ml;Supersaturated Calcium Phosphate
2 A Randomized Study on the Effects of Lactobacillus Brevis CD2 in the Prevention of Radio and Chemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients. Unknown status NCT01707641 Phase 4
3 A Comparison of Oral Controlled-release Morphine With Transdermal Fentanyl in Nasopharyngeal Cancer Patients With Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy Unknown status NCT04292990 Phase 4 Fentanyl;Morphine
4 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
5 A Pilot Study Evaluating the Efficacy of Apremilast in the Treatment of Subjects With Severe Recurrent Aphthous Stomatitis (RAS) Completed NCT03690544 Phase 4 Apremilast 30mg
6 Local Administration of Morphine: An Evaluation of the Analgesic Effect at Stomatitis in Children Completed NCT00357942 Phase 4 morphine solution for injection;Placebo;morphine mouthwash
7 Clinical Evaluation of an Experimental Solution Based on Ricinus Communis Compared to Sodium Hypochlorite for Denture Cleansing Completed NCT02407834 Phase 4
8 Evaluation of the Efficacy of a Hexetidine- and Chlorobutanol-based Mouthwash in the Symptomatic Treatment of Oral Lesions Due to Removable Prostheses: a Prospective, Randomized, Triple-blind Controlled Clinical Trial Completed NCT01115049 Phase 4 chlorobutanol, hexetidine;Chlorhexidine
9 A Randomized, Double-blind Study to Evaluate the Efficacy of MuGard Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck Completed NCT01283906 Phase 4
10 Phase IV Study on the Feasibility of a Preventative/Therapeutic Approach With Benzydamine Oromucosal Solution in Radiation-induced Oral Mucositis (OM) in Patients With Head and Neck Cancer (HNC) Recruiting NCT05055726 Phase 4 Benzydamine Hydrochloride 0.15% w/v oromucosal solution
11 Clinical Study of the Effects of Compound Kushen Injection on Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. Recruiting NCT04204382 Phase 4 Levofloxacin Injection;Compound Kushen Injection（CKI）
12 OZOCLO: a Randomized Clinical Trial for Prevention of Oral Mucositis Not yet recruiting NCT05211622 Phase 4 1. alpha acid lipoic - tables;2. ozonated oil - mouthwash;3. chlorhexidine 0,2% - mouthwash;4. sodium bicarbonate 5% solution - mouthwash
13 An Adaptive Design, Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash ("Magic Mouthwash") for the Management of Oral Mucositis Associated With High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients Terminated NCT03490396 Phase 4
14 Prospective, Open-label, Randomized, Control Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine Withdrawn NCT01288625 Phase 4 Amifostine
15 The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients Unknown status NCT01099891 Phase 3 rhEGF;Placebo
16 A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02085694 Phase 2, Phase 3 Lactobacillus brevis CD2
17 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
18 Evaluation of Low-energy Laser Therapy for Prevention and Reduction of Severity of Oral Mucositis in Children "Mucositis Laser 1" Unknown status NCT01007617 Phase 2, Phase 3
19 A Randomized Trial to Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation. Unknown status NCT04080622 Phase 3 Selenium;Placebos
20 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
21 Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic in Elderly People Completed NCT02818803 Phase 3 Miconazole
22 Effectiveness of Topical Hyaluronic Acid Versus Chlorhexidine Mouthwashes in the Treatment of Recurrent Aphthous Stomatitis: A Randomized Clinical Trial Completed NCT04265001 Phase 3 Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash
23 Prevention of Recurrent Aphthous Stomatitis Using Vitamins Completed NCT00527306 Phase 3
24 A Randomized,Controlled Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis. Completed NCT02303197 Phase 3 ChiNing decoction
25 A Double-Blind, Randomized, Vehicle-Controlled Study Comparing the Safety and Efficacy of Benzydamine HCl 0.15% Oral Rinse Including a Separate Open-Label Standard of Care Arm in Subjects With Radiation-Induced Mucositis Completed NCT00051441 Phase 3 Benzydamine Hydrochloride 0.15% Oral Rinse
26 LAMPO: Multicenter Randomized Double-blind Controlled Trial to Evaluate the Efficacy of Laser Therapy for Treatment of Oral Mucositis Induced by Chemotherapy in Children Completed NCT02762019 Phase 3
27 A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2 Completed NCT00001812 Phase 3 Nystatin
28 Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Radiotherapy With Concurrent Chemotherapy (RT/CT) Completed NCT00101582 Phase 3 Placebo;palifermin;cisplatin chemotherapy
29 A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Recombinant Human Keratinocyte Growth Factor for Reduction of Mucositis in Patients With Hematologic Malignancies Undergoing Total Body Irradiation and High-dose Chemotherapy With Autologous PBPC Transplantation Completed NCT00041665 Phase 3 Recombinant Human Keratinocyte Growth Factor
30 Evaluating the Effectiveness of Topical Morphine Compared With a Routine Mouthwash in Managing Cancer Treatment-induced Mucositis in Patients With Head and Neck Cancer in Isfahan Completed NCT01837446 Phase 2, Phase 3 2% morphine solution;Magnesium aluminum hydroxide;2% viscous lidocaine;Diphenhydramine
31 Phase III Randomized Double-blind Cross-over Trial of Caphosol® Versus NaCl 0.9% in the Relief of Oral Mucositis in Renal Cell Carcinoma, Hepatocellular Carcinoma, and Gastrointestinal Stromal Tumor Patients Receiving Targeted Therapy Completed NCT01265810 Phase 3
32 Phase III Trial of Low-level Laser Therapy to Prevent Induced Oral Mucositis in Head and Neck Cancer Patients Submitted to Concurrent Chemoradiation Completed NCT01439724 Phase 3
33 A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin for Reduction in Severity of Oral Mucositis in Subjects With Multiple Myeloma Receiving Melphalan Followed by Autologous Blood Stem Cell Transplantation Completed NCT00434161 Phase 3 Palifermin before only;Placebo;Palifermin before and after
34 A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT02229539 Phase 3 doxepin hydrochloride oral solution;DLA (diphenhydramine, lidocaine and antacids) rinse
35 Management of Mucositis With GM-CSF (Sargramostim) Mouthwash Study Protocol Completed NCT00293462 Phase 3
36 Effect of Ascorbic Acid Oral Supplementation in Assessing the Severity of Oral Mucositis in Chemo-radiation Therapy of Head and Neck Cancers. Completed NCT02868151 Phase 2, Phase 3 Ascorbic Acid;Zinc acetate
37 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) for Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer Receiving 5-FU and Leucovorin as Adjuvant Therapy Completed NCT00393822 Phase 2, Phase 3 palifermin;placebo
38 A Randomized, Blinded, Active-control Trial of Palifermin (rHuKGF) to Evaluate Oral Mucositis in Subjects With Hematologic Malignancies Undergoing Fractionated Total Body Irradiation (fTBI) and High Dose Chemotherapy With Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation Completed NCT00109031 Phase 3 palifermin;Cyclophosphamide;Etoposide;Placebo
39 Clinical Effect of Probiotic Use Bifidobacterium Animalis Subsp. Lactis as Adjunctive Therapy in Non-surgical Treatment of Periimplant Mucositis: a Randomized Controlled Trial Completed NCT04187222 Phase 3
40 Evaluate Safety and Tolerability and Compare Absorption/Distribution Kinetics of a Single 100 Mcg Dose of Fentanyl Sublingual Spray (Fentanyl SL Spray) in Cancer Subjects With or Without Oral Mucositis Completed NCT00956254 Phase 3 Fentanyl sublingual spray
41 A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer Completed NCT00615420 Phase 3
42 Randomized Cross-over Study of Curcumin for Prevention of Oral Mucositis in Children Receiving Doxorubicin Based Chemotherapy. Completed NCT00475683 Phase 3
43 A Comparison of Acute Oral Mucositis Between Morning and Afternoon Radiotherapy in Patients Receiving Radiation Treatment for Cancer of the Head and Neck Completed NCT00004234 Phase 3
44 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Assess the Efficacy and Safety of SBG on Oral Mucositis in Head and Neck Cancer Patients Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT00790322 Phase 3 SBG
45 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
46 Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation : a Randomized Double Blind Multicenter Prospective Phase III Trial Completed NCT02696408 Phase 3
47 Laser Therapy Associated With Photodynamic Therapy in the Treatment of Oral Mucositis Induced by Chemotherapy in Young Patients: Randomized Blind Clinical Trial Completed NCT02555501 Phase 3
48 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
49 Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Adjuvant Radiotherapy and Chemotherapy(RT/CT) Completed NCT00131638 Phase 3 Placebo;Palifermin
50 A Phase II/III Blinded Randomized Trial to Determine the Efficacy of Low Energy Diode Laser Therapy (650 nm or 780 nm) to Prevent Oral Mucositis Following Bone Marrow Transplantation Completed NCT00024037 Phase 2, Phase 3

Search NIH Clinical Center for Stomatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


carbamide peroxide
Sucralfate

Cochrane evidence based reviews: stomatitis

Sources

Genetic Tests for Stomatitis

About this section
Sources

Anatomical Context for Stomatitis

About this section

Organs/tissues related to Stomatitis:

MalaCards : Bone Marrow, Breast, Lung, Myeloid, Liver, T Cells, Bone
Sources

Publications for Stomatitis

About this section

Articles related to Stomatitis:

(show top 50) (show all 15705)
# Title Authors PMID Year
1
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. 53 62
17520255 2008
2
DPYD*2A mutation: the most common mutation associated with DPD deficiency. 53 62
17165084 2007
3
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. 53 62
17409804 2007
4
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. 53 62
15550581 2004
5
Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. 53 62
15539918 2004
6
Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. 53 62
12352929 2002
7
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. 53 62
10473079 1999
8
Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. 53 62
9007910 1997
9
High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity. 53 62
7524888 1994
10
Characterization and functional analysis of chicken dsRNA binding protein hnRNPU. 62
36044969 2023
11
Oral health-related quality of life in children with celiac disease. 62
35918470 2022
12
Vesicular stomatitis virus sensitizes immunologically cold tumors to checkpoint blockade by inducing pyroptosis. 62
36096276 2022
13
A new anterograde trans-synaptic tracer based on Sindbis virus. 62
35662226 2022
14
Cloning and codon optimization of a novel feline interferon omega gene for production by Pichia pastoris and its antiviral efficacy in polyethylene glycol-modified form. 62
35068319 2022
15
Functional characterization of bat IRF1 in IFN induction. 62
35933044 2022
16
Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001). 62
35767198 2022
17
OTUD7B deubiquitinates SQSTM1/p62 and promotes IRF3 degradation to regulate antiviral immunity. 62
35100065 2022
18
SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376. 62
36194133 2022
19
Matrix metalloproteinase 3 restricts viral infection by enhancing host antiviral immunity. 62
35940311 2022
20
Oral chemical burns caused by topical application of policresulen: a case report. 62
36262098 2022
21
Codon-optimization of the respiratory syncytial virus (RSV) G protein expressed in a vesicular stomatitis virus (VSV) vector improves immune responses in a cotton rat model. 62
36096069 2022
22
Role of vitamin B12 in treating recurrent aphthous stomatitis: A review. 62
33103958 2022
23
Dual roles of ANGPTL4 in multiple inflammatory responses in stomatitis mice. 62
35819554 2022
24
From functional genomics of vero cells to CRISPR-based genomic deletion for improved viral production rates. 62
35869699 2022
25
Trim69 is a microtubule regulator that acts as a pantropic viral inhibitor. 62
36251989 2022
26
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. 62
36244398 2022
27
Electrospun patch delivery of anti-TNFα F(ab) for the treatment of inflammatory oral mucosal disease. 62
35973471 2022
28
The Transient Receptor Potential Vanilloid 2 (TRPV2) Channel Facilitates Virus Infection Through the Ca2+ -LRMDA Axis in Myeloid Cells. 62
36261399 2022
29
Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials. 62
36208978 2022
30
SERINC5 restricts influenza virus infectivity. 62
36223419 2022
31
Sleep quality and risk of recurrent aphthous ulcers: A Spanish cohort study. 62
34242451 2022
32
Establishment of a Culex tarsalis (Diptera: Culicidae) Cell Line and its Permissiveness to Arbovirus Infection. 62
36260075 2022
33
Brucellosis: A Rare Cause of Febrile Neutropenia in a Child. 62
35830519 2022
34
Cell-impermeable staurosporine analog targets extracellular kinases to inhibit HSV and SARS-CoV-2. 62
36245045 2022
35
Atomic model of vesicular stomatitis virus and mechanism of assembly. 62
36216930 2022
36
In vitro antimicrobial effects of chitosan on microcosm biofilms of oral candidiasis. 62
35914573 2022
37
Characterization, antifungal evaluation against Candida spp. strains, and application of nystatin:β-cyclodextrin inclusion complexes. 62
36263476 2022
38
Silver-loaded mesoporous silica nanoparticles enhanced the mechanical and antimicrobial properties of 3D printed denture base resin. 62
36037709 2022
39
White Tongue Because of Uremic Stomatitis as a Sign of Advanced Kidney Disease. 62
36168856 2022
40
Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. 62
36240432 2022
41
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. 62
36099710 2022
42
Synchronous disease onset and flares in siblings with PFAPA. 62
36199113 2022
43
Vesicular Stomatitis Virus Isolated from a Bovine Brain Sample in Costa Rica. 62
36125285 2022
44
Dynamic Actin Filament Traps Mediate Active Diffusion of Vesicular Stomatitis Virus Ribonucleoproteins. 62
36135365 2022
45
Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial. 62
35526266 2022
46
Rottlerin plays an antiviral role at early and late steps of Zika virus infection. 62
35934227 2022
47
The interaction of viral fusion peptides with lipid membranes. 62
36110043 2022
48
Protein disulfide isomerases (PDIs) negatively regulate ebolavirus structural glycoprotein expression in the endoplasmic reticulum (ER) via the autophagy-lysosomal pathway. 62
35130104 2022
49
IBCL-271 Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study. 62
36164104 2022
50
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 fusion or other rearrangement. 62
36206041 2022
Sources

Variations for Stomatitis

About this section
Sources

Expression for Stomatitis

About this section
Search GEO for disease gene expression data for Stomatitis.
Sources

Pathways for Stomatitis

About this section

Pathways related to Stomatitis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.58 TRIM41 TNF RSAD2 RIGI NUP98 IFNA2
2
Cytokine Signaling in Immune system 66
Show member pathways
 12.81 ADAR BST2 CSF2 EIF2AK2 IFI35 IFITM2
3
Toll-like receptor signaling pathway 74
Show member pathways
 12.58 TNF RIGI IFNA2 EIF2AK2 ADAR
4
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.36 ADAR BST2 IFI35 IFITM2 IFITM3 IFNA2
5
DDX58/IFIH1-mediated induction of interferon-alpha/beta 66
Show member pathways
 12.21 RIGI IFNA2 ATG5 ATG12
6
Cytosolic sensors of pathogen-associated DNA 66
Show member pathways
 12.2 RIGI IFNA2 ATG5 ATG12 ADAR
7
Ebola virus infection in host 74
11.81 RIGI EIF2AK2 BST2
8
Interferon gamma signaling 66
Show member pathways
 11.81 RSAD2 RIGI NUP98 IFNA2 IFITM3 IFITM2
9
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.75 TNF IFNA2 CSF2
10
Host-pathogen interaction of human coronaviruses - interferon induction 74
Show member pathways
 11.65 RIGI IFNA2 EIF2AK2 ADAR
11
Dendritic Cells Developmental Lineage Pathway 65
11.48 TNF IFNA2 CSF2
12
SARS-CoV-2 innate immunity evasion and cell-specific immune response 74
11.33 TNF RIGI NUP98 CSF2
13
Pathways of nucleic acid metabolism and innate immune sensing 74
10.7 RIGI ADAR
Sources

GO Terms for Stomatitis

About this section

Cellular components related to Stomatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Atg12-Atg5-Atg16 complex GO:0034274 8.92 ATG5 ATG12

Biological processes related to Stomatitis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.25 RSAD2 RIGI IFITM3 IFITM2 IFI35 EIF2AK2
2 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.04 TNF IFI35 EIF2AK2
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.03 TNF IFNA2 CSF2
4 negative regulation of viral genome replication GO:0045071 10.03 BST2 EIF2AK2 IFITM2 IFITM3 RSAD2 TNF
5 type I interferon-mediated signaling pathway GO:0060337 9.99 IFNA2 IFITM3 IFITM2
6 immune system process GO:0002376 9.97 RSAD2 RIGI IFITM3 IFITM2 IFI35 EIF2AK2
7 response to type II interferon GO:0034341 9.93 IFITM3 IFITM2 BST2
8 negative regulation of viral entry into host cell GO:0046597 9.91 IFNA2 IFITM3 IFITM2
9 response to virus GO:0009615 9.86 ADAR BST2 EIF2AK2 IFITM2 IFITM3 RIGI
10 autophagy of nucleus GO:0044804 9.85 ATG5 ATG12
11 response to interferon-beta GO:0035456 9.85 BST2 IFITM2 IFITM3
12 response to interferon-alpha GO:0035455 9.85 IFITM3 IFITM2 EIF2AK2 BST2 ADAR
13 regulation of autophagosome maturation GO:1901096 9.84 ATG5 ATG12
14 positive regulation of leukocyte proliferation GO:0070665 9.83 CSF2 BST2
15 C-terminal protein lipidation GO:0006501 9.8 ATG12 ATG5
16 positive regulation of viral translation GO:1904973 9.78 ATG5 ATG12
17 defense response to virus GO:0051607 9.62 TRIM41 RSAD2 RIGI NDUFAF4 IFNA2 IFITM3
Sources

Sources for Stomatitis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....